UC-112

Name: UC-112
Brand: MedChemExpress
SKU: HY-12842
Rating: 4.5 (1 reviews)

Cat. No.: HY-12842 Purity: 98.92%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

UC-112 is a XIAP inhibitor with anticancer activity. UC-112 selectively downregulates and degrades survivin via the ubiquitin-mediated proteasomal degradation pathway. UC-112 reduces XIAP levels in in vivo tumor models. UC-112 activates caspase-3/7 and caspase-9, and induces cancer cell apoptosis. UC-112 is applicable to studies on melanoma, prostate cancer and cancer-related research.

For research use only. We do not sell to patients.

UC-112 Chemical Structure

CAS No. : 383392-66-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All IAP Isoform Specific Products:

View All Isoforms

cIAP cIAP-1 cIAP-2 XIAP

View All Caspase Isoform Specific Products:

View All Isoforms

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	1.6 μM Compound: 4; UC-112	Cytotoxicity against human A-375 cells assessed as inhibition of cell growth Cytotoxicity against human A-375 cells assessed as inhibition of cell growth	[PMID: 38092421]
DU-145	IC₅₀	3.4 μM Compound: 4; UC-112	Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth	[PMID: 38092421]
M14	IC₅₀	2.5 μM Compound: 4; UC-112	Antiproliferative activity against human M14 cells assessed as reduction cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human M14 cells assessed as reduction cell viability incubated for 48 hrs by MTT assay	[PMID: 38092421]
M14	IC₅₀	3.2 μM Compound: 4; UC-112	Antiproliferative activity against human M14 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human M14 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 38092421]
PC-3	IC₅₀	0.7 μM Compound: 4; UC-112	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth	[PMID: 38092421]

In Vitro

UC-112 (3-10 μM; 48 h) potently inhibits proliferation of A375, M14, PC-3, and DU145 cancer cells with IC₅₀ values ranging from 0.7 to 3.4 μM^[1].
UC-112 (4 μM; 24-48 h) potently activates caspase-3/7 and caspase-9 activities in A375 and PC-3 cancer cells after 24 or 48 hours of incubation^[1].
UC-112 (400 nM-10 μM; 24 h) selectively downregulates survivin levels in A375, PC-3, and DU145 cancer cells^[1].
UC-112-induced survivin downregulation in A375, PC-3, and DU145 cancer cells is rescued by proteasome inhibition, indicating involvement of ubiquitin-mediated degradation^[1].
UC-112 (1-4 μM; 24 h) alters cell cycle distribution of A375 melanoma cells, causing S phase accumulation at 1 μM and G₀/G₁ phase arrest with apoptotic sub-G₁ events at 4 μM after 24-hour incubation^[1].
UC-112 potently inhibits proliferation of both M14 and P-gp-overexpressing M14/MDR1 multidrug-resistant melanoma cells with low resistance, having IC₅₀ values of 0.87 μM and 1.80 μM, respectively^[1].
UC-112 (72 h) inhibits the proliferation of A375 and M14 human melanoma cells with IC₅₀ values of 1.9 ± 0.6 μM and 2.1 ± 0.4 μM, respectively^[2].
UC-112 (72 h) inhibits the proliferation of P-gp overexpressing M14/MDR1 human melanoma cells with an IC₅₀ of 3.2 ± 0.5 μM and a resistance index of 1.5^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	A375, M14, PC-3, DU145
Concentration:	3 μM; 10 μM
Incubation Time:	48 h
Result:	Achieved 50.7% growth inhibition in A375 cells and 81.1% growth inhibition in M14 cells at 3 μM after 48-hour incubation. Achieved 65.0% growth inhibition in A375 cells and 99.6% growth inhibition in M14 cells at 10 μM after 48-hour incubation. Had IC₅₀ values of 1.6 μM (A375), 2.5 μM (M14), 0.7 μM (PC-3), and 3.4 μM (DU145).

Western Blot Analysis^[1]

Cell Line:	A375, PC-3, DU145
Concentration:	400 nM; 1 μM, 4 μM; 10 μM
Incubation Time:	24 h
Result:	Suppressed survivin levels in A375, PC-3, and DU145 cells in a dose-dependent manner at 4 μM and 10 μM for 24 hours, achieving 94% and 97% survivin inhibition in A375 cells at 4 μM and 10 μM, respectively, with weaker inhibition of XIAP, cIAP1, and cIAP2. Significantly downregulated survivin levels (greater than 50% compared to control) in A375 cells at 400 nM for 24 hours. Required a concentration of 1 μM for 24 hours to achieve similar survivin downregulation in PC-3 cells.

Western Blot Analysis^[1]

Cell Line:	A375, PC-3, DU145
Concentration:	4 μM; 10 μM
Incubation Time:	24 h
Result:	Rescued survivin levels in PC-3 and DU145 cells when coincubated with 10 μM MG-132 at 4 μM or 10 μM for 24 hours. Rescued survivin levels in A375 cells when pretreated with 20 μM or 50 μM MG-132 for 6 hours followed by incubation at 4 μM or 10 μM for 24 hours.

Cell Cycle Analysis^[1]

Cell Line:	A375
Concentration:	1 μM; 4 μM
Incubation Time:	24 h
Result:	Caused A375 cells to accumulate in S phase with a concurrent reduction in G₂/M phase cells at 1 μM for 24 hours. Caused 76% of A375 cells to accumulate in G₀/G₁ phase (compared to 51% in vehicle control), with a reduction in G₂/M phase cells (13% compared to 21% in vehicle control) and increased sub-G₁ events indicating apoptosis at 4 μM for 24 hours.

In Vivo

UC-112 (20-40 mg/kg; i.p.; once daily, 5 days per week; 3 weeks) inhibits human melanoma tumor growth in a dose-dependent manner in nude mice, achieving 65.6% TGI at 20 mg/kg and 95.2% TGI at 40 mg/kg, while reducing IAP protein levels and inducing tumor cell apoptosis without significant body weight loss^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	nude mice (7-8-week-old male; subcutaneous inoculation of human melanoma cells)^[1]
Dosage:	20 mg/kg; 40 mg/kg
Administration:	i.p.; once daily, 5 days per week; 3 weeks
Result:	Achieved 65.59% tumor growth inhibition (TGI) compared to vehicle control. Achieved 95.23% TGI, with average tumor weight reduced to 13.56% of the vehicle control group's average tumor weight. Reduced both survivin and X chromosome-linked IAP (XIAP) levels in fresh tumor lysates. Induced extensive tumor cell death observed via hematoxylin and eosin staining. Caused dose-dependent increases in tumor cell apoptosis detected via terminal deoxynucleotidyl transferase-mediated digoxigenin-deoxyuridine nick-end labeling (TUNEL) assay. Showed no >10% body weight loss in treated mice.

Molecular Weight

348.44

Formula

C₂₂H₂₄N₂O₂

CAS No.

383392-66-3

Appearance

Solid

Color

White to off-white

SMILES

OC1=C2N=CC=CC2=C(COCC3=CC=CC=C3)C=C1CN4CCCC4

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL (95.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8699 mL	14.3497 mL	28.6993 mL
5 mM	0.5740 mL	2.8699 mL	5.7399 mL
10 mM	0.2870 mL	1.4350 mL	2.8699 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.17 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (7.17 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.17 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.92%

Select Batch:

Data Sheet (283 KB) SDS (251 KB)

COA (253 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

References

[1]. Wang J, et al. Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors. J Pharmacol Exp Ther. 2014;349(2):319-329. [Content Brief]

[2]. Wang Q, et al. Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors. Eur J Med Chem. 2018;149:211-224. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8699 mL	14.3497 mL	28.6993 mL	71.7484 mL
	5 mM	0.5740 mL	2.8699 mL	5.7399 mL	14.3497 mL
	10 mM	0.2870 mL	1.4350 mL	2.8699 mL	7.1748 mL
	15 mM	0.1913 mL	0.9566 mL	1.9133 mL	4.7832 mL
	20 mM	0.1435 mL	0.7175 mL	1.4350 mL	3.5874 mL
	25 mM	0.1148 mL	0.5740 mL	1.1480 mL	2.8699 mL
	30 mM	0.0957 mL	0.4783 mL	0.9566 mL	2.3916 mL
	40 mM	0.0717 mL	0.3587 mL	0.7175 mL	1.7937 mL
	50 mM	0.0574 mL	0.2870 mL	0.5740 mL	1.4350 mL
	60 mM	0.0478 mL	0.2392 mL	0.4783 mL	1.1958 mL
	80 mM	0.0359 mL	0.1794 mL	0.3587 mL	0.8969 mL

UC-112 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

UC-112

Customer Review

UC-112 Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All IAP Isoform Specific Products:

View All Caspase Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

UC-112 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

UC-112 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report